Lynch syndrome detection in patients with cancer has immediate implications for therapy, cancer surveillance, genetic counselling, and chemoprevention with aspirin.1 Although all new diagnoses of colorectal and endometrial cancers in the UK are recommended by the National Institute for Health and Care Excellence (NICE) to undergo diagnostic testing for Lynch syndrome, many less commonly diagnosed Lynch syndrome spectrum cancers, including skin cancers such as sebaceous carcinoma,2 are not automatically tested, which results in missed opportunities for improved care in affected patients and their families.